Lung cancer - non-small cell and Gastrointestinal inflammation

Summary:

Gastrointestinal inflammation is found among people with Lung cancer - non-small cell, especially for people who are male, 60+ old.

The study analyzes which people have Gastrointestinal inflammation with Lung cancer - non-small cell. It is created by eHealthMe based on reports of 20 people who have Lung cancer - non-small cell from the Food and Drug Administration (FDA), and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Aug, 17, 2022

20 people who have Lung Cancer - Non-Small Cell and Gastrointestinal Inflammation are studied.


What is Lung cancer - non-small cell?

Lung cancer - non-small cell (lung cancer) is found to be associated with 780 drugs and 501 conditions by eHealthMe.

What is Gastrointestinal inflammation?

Gastrointestinal inflammation (inflammation of stomach and intestine) is found to be associated with 773 drugs and 511 conditions by eHealthMe.

Number of Gastrointestinal inflammation in Lung cancer - non-small cell reports submitted per year:

Would you have Gastrointestinal inflammation when you have Lung cancer - non-small cell?

Gender of people who have Lung Cancer - Non-Small Cell and experienced Gastrointestinal Inflammation *:

  • female: 47.37 %
  • male: 52.63 %

Age of people who have Lung Cancer - Non-Small Cell and experienced Gastrointestinal Inflammation *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 0.0 %
  • 40-49: 0.0 %
  • 50-59: 20 %
  • 60+: 80 %

Common co-existing conditions for these people *:

  1. Pain: 3 people, 15.00%
  2. High Blood Pressure: 3 people, 15.00%
  3. High Blood Cholesterol: 1 person, 5.00%

Common drugs taken by these people *:

  1. Tarceva: 3 people, 15.00%
  2. Folic Acid: 3 people, 15.00%
  3. Darvocet: 3 people, 15.00%
  4. Keytruda: 3 people, 15.00%
  5. Plaquenil: 3 people, 15.00%
  6. Gilotrif: 2 people, 10.00%
  7. Pemetrexed: 2 people, 10.00%
  8. Metoprolol Succinate: 2 people, 10.00%
  9. Duragesic-100: 2 people, 10.00%
  10. Phenergan: 2 people, 10.00%

Common symptoms for these people *:

  1. Diarrhea: 6 people, 30.00%
  2. Thrombocytopenia (decrease of platelets in blood): 4 people, 20.00%
  3. Dehydration (dryness resulting from the removal of water): 3 people, 15.00%
  4. Gastrointestinal Haemorrhage (bleeding gastrointestinal tract): 3 people, 15.00%
  5. Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 2 people, 10.00%
  6. Malignant Neoplasm Progression (cancer tumour came back): 2 people, 10.00%
  7. Fatigue (feeling of tiredness): 2 people, 10.00%
  8. Leukopenia (less number of white blood cells in blood): 2 people, 10.00%
  9. Nausea (feeling of having an urge to vomit): 2 people, 10.00%
  10. Colitis (inflammation of colon): 2 people, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take medications and have Gastrointestinal inflammation?

Check whether Gastrointestinal inflammation is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

Treatments, associated drugs and conditions:

COVID vaccines that are related to Gastrointestinal inflammation:

Common drugs associated with Gastrointestinal inflammation:

All the drugs that are associated with Gastrointestinal inflammation:

Common conditions associated with Gastrointestinal inflammation:

All the conditions that are associated with Gastrointestinal inflammation:

How the study uses the data?

The study is based on Gastrointestinal inflammation and Lung cancer - non-small cell, and their synonyms.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: